Literature DB >> 16446700

Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells.

Polyxenie E Spoerri1, Aqeela Afzal, Sergio Li Calzi, Lynn C Shaw, Jun Cai, Hao Pan, Michael Boulton, Maria B Grant.   

Abstract

PURPOSE: To evaluate whether transfection of human retinal endothelial cells (HRECs) with plasmids expressing ribozymes designed to specifically cleave the mRNA and reduce expression of either vascular endothelial growth factor (VEGF) receptor-1 (VEGFR-1), or VEGF receptor-2 (VEGFR-2), or insulin-like growth factor-I receptor (IGF-IR) modulates occludin expression in high glucose-treated cells.
METHODS: Hammerhead ribozymes that specifically cleave the human VEGFR-1, VEGFR-2, and IGF-IR mRNAs were developed and tested in vitro to determine ribozyme kinetics and cleavage specificity. HRECs grown in normal (5.5 mM) and high (25 mM) glucose medium were transfected with plasmids expressing VEGFR-1, VEGFR-2, or IGF-IR hammerhead ribozymes. VEGF and IGF-I levels were measured in conditioned medium of HREC exposed to high glucose conditions, and the effect of varying glucose concentration on VEGFR-1 and VEGFR-2 phosphorylation was examined. The amount of the tight junction protein occludin was determined by western analysis, and the protein was localized by immunohistochemistry.
RESULTS: Exposure of HRECs to high glucose resulted in increased VEGF and IGF-I expression as well as VEGFR-2 but not VEGFR-1 phosphorylation. Immunocytochemistry and western analysis revealed that HRECs exposed to high glucose had reduced occludin staining and protein expression, respectively. Transfection of HRECs exposed to high glucose with either VEGFR-1, VEGFR-2, or IGF-IR hammerhead ribozymes prevented the downregulation of occludin protein expression.
CONCLUSIONS: Our studies support that activation of VEGFR-1, VEGFR-2, and IGF-IR by high glucose contributes to disruption of tight junctions by decreasing occludin expression and may be important in the pathogenesis of blood-retinal barrier dysfunction in diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16446700

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  15 in total

Review 1.  IGF-1 and cardiovascular disease.

Authors:  Yusuke Higashi; Sandeep Gautam; Patrick Delafontaine; Sergiy Sukhanov
Journal:  Growth Horm IGF Res       Date:  2019-01-31       Impact factor: 2.372

2.  Occludin downregulation in high glucose is regulated by SSTR2 via the VEGF/NRP1/Akt signaling pathway in RF/6A cells.

Authors:  Mengling Li; Shuaiwei Wang; Songjiang Wang; Lei Zhang; Dongdong Wu; Ruisheng Yang; Ailing Ji; Yanzhang Li; Jun Wang
Journal:  Exp Ther Med       Date:  2017-06-22       Impact factor: 2.447

3.  MicroRNA-301a-3p promotes diabetic retinopathy via regulation of six-transmembrane epithelial antigen of prostate 4.

Authors:  Yingmin Wang; Lijuan Gao; Zhili Li; Xingyou Ma
Journal:  Inflamm Res       Date:  2021-02-20       Impact factor: 4.575

Review 4.  Models of retinal diseases and their applicability in drug discovery.

Authors:  Goldis Malek; Julia Busik; Maria B Grant; Mayur Choudhary
Journal:  Expert Opin Drug Discov       Date:  2018-01-30       Impact factor: 6.098

5.  Gene delivery nanoparticles specific for human microvasculature and macrovasculature.

Authors:  Ron B Shmueli; Joel C Sunshine; Zhenhua Xu; Elia J Duh; Jordan J Green
Journal:  Nanomedicine       Date:  2012-02-01       Impact factor: 5.307

6.  Vitreous inflammatory factors and serous retinal detachment in central retinal vein occlusion: a case control series.

Authors:  Hidetaka Noma; Hideharu Funatsu; Tatsuya Mimura; Shuichiro Eguchi
Journal:  J Inflamm (Lond)       Date:  2011-12-12       Impact factor: 4.981

7.  Diosmin alleviates retinal edema by protecting the blood-retinal barrier and reducing retinal vascular permeability during ischemia/reperfusion injury.

Authors:  Nianting Tong; Zhenzhen Zhang; Wei Zhang; Yating Qiu; Yuanyuan Gong; Lili Yin; Qinghua Qiu; Xingwei Wu
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

8.  Protection of blood retinal barrier and systemic vasculature by insulin-like growth factor binding protein-3.

Authors:  Yagna P R Jarajapu; Jun Cai; Yuanqing Yan; Sergio Li Calzi; Jennifer L Kielczewski; Ping Hu; Lynn C Shaw; Sue M Firth; Tailoi Chan-Ling; Michael E Boulton; Robert C Baxter; Maria B Grant
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

9.  Endothelial deficiency of insulin-like growth factor-1 receptor reduces endothelial barrier function and promotes atherosclerosis in Apoe-deficient mice.

Authors:  Yusuke Higashi; Sergiy Sukhanov; Shaw-Yung Shai; Svitlana Danchuk; Patricia Snarski; Zhaohui Li; Xuwei Hou; Milton H Hamblin; T Cooper Woods; Meifang Wang; Derek Wang; Hong Yu; Ronald J Korthuis; Tadashi Yoshida; Patrice Delafontaine
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-08-14       Impact factor: 5.125

10.  The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress.

Authors:  Jun Wang; Shuaiwei Wang; Mengling Li; Dongdong Wu; Fang Liu; Ruisheng Yang; Shaoping Ji; Ailing Ji; Yanzhang Li
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.